Cmic Holdings Co
Cmic Holdings Co., a prominent player in the pharmaceutical and biotechnology industry, is headquartered in Japan (JP) and operates extensively across Asia and beyond. Founded in 2006, the company has established itself as a leader in contract research and manufacturing services, catering to a diverse clientele in the life sciences sector. Cmic Holdings is renowned for its comprehensive range of services, including drug development, clinical trial management, and regulatory affairs. What sets them apart is their commitment to innovation and quality, ensuring that clients receive tailored solutions that meet stringent industry standards. With a strong market position, Cmic Holdings has achieved significant milestones, including strategic partnerships and expansions that enhance its service offerings.
DitchCarbon Score
How does Cmic Holdings Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cmic Holdings Co's score of 39 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cmic Holdings Co's reported carbon emissions
In 2024, CMIC Holdings Co., Ltd. reported total carbon emissions of approximately 8,000,000 kg CO2e, comprising 1,000,000 kg CO2e from Scope 1 and 7,000,000 kg CO2e from Scope 2. This marks a continuation of their emissions profile, as similar figures were recorded in 2023, where total emissions also reached about 8,000,000 kg CO2e, with the same breakdown across scopes. CMIC Holdings has set ambitious climate commitments, aiming for a 42% reduction in absolute Scope 1 and Scope 2 greenhouse gas emissions by FY2030, using FY2023 as the baseline year. Additionally, the company has committed to a 35% reduction in absolute Scope 3 emissions within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. The company has not disclosed any Scope 3 emissions data, which is often a significant component of total corporate emissions. However, their proactive stance on emissions reduction reflects a growing commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cmic Holdings Co is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
